QRG Capital Management Inc. Grows Stake in IQVIA Holdings Inc. (NYSE:IQV)

QRG Capital Management Inc. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 51.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,403 shares of the medical research company's stock after purchasing an additional 2,871 shares during the period. QRG Capital Management Inc.'s holdings in IQVIA were worth $1,481,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. American National Bank & Trust acquired a new stake in IQVIA in the 1st quarter worth about $26,000. ST Germain D J Co. Inc. boosted its stake in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA during the fourth quarter worth approximately $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the 4th quarter valued at $44,000. Finally, Zions Bancorporation N.A. lifted its holdings in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Up 0.2%

NYSE:IQV traded up $0.35 during midday trading on Friday, reaching $154.96. The company had a trading volume of 2,905,629 shares, compared to its average volume of 1,635,737. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The firm has a market capitalization of $26.81 billion, a price-to-earnings ratio of 21.11, a PEG ratio of 1.69 and a beta of 1.28. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The stock's fifty day simple moving average is $148.21 and its 200-day simple moving average is $176.10.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.54 earnings per share. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on IQV. Wall Street Zen lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Truist Financial dropped their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Barclays lowered their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.